{"entity":{"id":"tar-210","kind":"drug","name":"TAR-210","aka":[],"tldr":"TAR-210 is an experimental small molecule (intravesical drug-releasing system) from Janssen Research & Development in phase 3 trials for bladder & urothelial cancer, aimed at FGFR2.","summary":"TAR-210 (JNJ-42756493) is a small molecule (intravesical drug-releasing system) developed by Janssen Research & Development. Its target is FGFR2 (the sponsor names FGFR (fibroblast growth factor receptor)). The sponsor states: An intravesical system that provides approximately two years of continuous local bladder delivery of erdafitinib, an FGFR inhibitor, for patients with high-risk non-muscle-invasive bladder cancer harbouring susceptible FGFR alterations. ClinicalTrials.gov describes the intervention as: TAR-210 will be administered intravesically. It is the investigational product in 1 recruiting or active industry-led phase 2 and phase 3 interventional cancer trial, including the phase 3 study NCT06919965 (A Study to Evaluate TAR-210 Versus Intravesical Chemotherapy Treatment in Participants With High Risk Non-Muscle-Invasive Bladder Cancer), in bladder & urothelial cancer. The largest, NCT06919965, plans to enrol 220 participants with primary completion expected 2028-04-06. Status reflects the highest phase registered on ClinicalTrials.gov; no efficacy results are recorded here.","status":"phase-3","asOf":"2026-09-11","links":[{"label":"ClinicalTrials.gov: trials of TAR-210","url":"https://clinicaltrials.gov/search?intr=JNJ-42756493"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["urothelial"],"sections":[],"technologies":[],"targets":["fgfr2"],"drugs":[],"companies":["johnson-johnson"],"institutions":[],"pathways":[],"terms":[],"trials":["nct06919965","nct06319820"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo ingestion (ClinicalTrials.gov v2 + sponsor pipeline pages)","editedOn":"2026-09-11"},"code":"JNJ-42756493","modality":"small molecule (intravesical drug-releasing system)","mechanism":"An intravesical system that provides approximately two years of continuous local bladder delivery of erdafitinib, an FGFR inhibitor, for patients with high-risk non-muscle-invasive bladder cancer harbouring susceptible FGFR alterations.","approvals":[],"mechanismSteps":[],"toxicity":[],"access":[],"regulatoryEvents":[]},"route":"/drugs/tar-210/","neighbours":{"cancer":[{"id":"urothelial","kind":"cancer","name":"Bladder & urothelial cancer","route":"/cancers/urothelial/"}],"target":[{"id":"fgfr2","kind":"target","name":"FGFR2","route":"/targets/fgfr2/"}],"company":[{"id":"johnson-johnson","kind":"company","name":"Johnson & Johnson","route":"/companies/johnson-johnson/"}],"trial":[{"id":"nct06919965","kind":"trial","name":"A Study to Evaluate TAR-210 Versus Intravesical Chemotherapy Treatment in Participants With High Risk Non-Muscle-Invasive Bladder Cancer","route":"/trials/nct06919965/"},{"id":"nct06319820","kind":"trial","name":"A Study to Evaluate TAR-210 Versus Single Agent Intravesical Cancer Treatment in Participants With Bladder Cancer","route":"/trials/nct06319820/"}]}}